Obesity and cardiovascular disease: Pathogenetic role of the metabolic syndrome and therapeutic implications

Journal of Diabetes and its Complications

Volumn 14, Issue 3, 2000, Pages 154-174

  Abate, Nicola ^a  

^a Center for Human Nutrition   (United States)

Author keywords

Cardiovascular disease; Insulin resistance; Metabolic syndrome; Obesity

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE DERIVATIVE; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; LIPID; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE PHOSPHATASE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; GENETIC PREDISPOSITION; HEALTH BEHAVIOR; HUMAN; HYPERTENSION; INSULIN METABOLISM; INSULIN RESISTANCE; LIFESTYLE; LIPID METABOLISM; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0033824123     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(00)00067-2     Document Type: Article

References (163)

1. Abate N., Garg A., Peshock R.M., Stray-Gundersen J., Adams-Huet B., Grundy S.M. Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM. Diabetes. 45(12):1996;1684-1693.
2. Abate N., Garg A., Peshock R.M., Stray-Gundersen J., Grundy S.M. Relationship of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest. 96:1995;88-98.
3. Abbott W.G., Lillioja S., Young A.A., Zawadzki J.K., Yki-Jarvinen H., Christin L., Howard B.V. Relationships between plasma lipoprotein concentrations and insulin action in an obese hyperinsulinemic population. Diabetes. 36(8):1987;897-904.
4. Ahmad F., Azevedo J., Cortright R., Dohm G.L., Goldstein B.J. Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J Clin Invest. 100:1997;449-458.
5. Almind K., Bjorbaek C., Vetergaard H., Hansen T., Echwald S., Pedersen O. Amino acid polymorphisms of insulin receptor substrate-1 in non-insulin dependent diabetes mellitus. Lancet. 342:1993;828-832.
6. Almind K., Frederiksen S.K., Ahlgren M.G., Urhammer S., Hansen T., Clausen J.O., Pedersen O. Common amino acid substitutions in insulin receptor substrate-4 are not associated with type II diabetes mellitus or insulin resistance. Diabetologia. 41:1998;969-974.
7. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 20(Suppl. 1):1997;S5-S13.
8. Balasse E.O., Ooms H.A. Role of plasma free fatty acids in the control of insulin secretion in man. Diabetologia. 9(2):1973;145-151.
9. Bennett P.H. Diabetes mellitus in Pima Indians. Lancet. 2(7722):1971;488-489.
10. Bergstrom R.W., Newell-Morris L.L., Leonetti D.L., Shuman W.P., Wahl P.W., Fujimoto W.Y. Association of elevated fasting C-peptide level and increased intra-abdominal fat distribution with development of NIDDM in Japanese-American men. Diabetes. 39(1):1990;104-111.
11. Bigazzi R., Bianchi S., Baldari G., Campese V.M. Clustering of cardiovascular risk factors in salt-sensitive patients with essential hypertension: role of insulin. Am J Hypertens. 9(1):1996;24-32.
12. Bijnen F.C., Caspersen C.J., Feskens E.J., Saris W.H., Mosterd W.L., Kromhout D. Physical activity and 10-year mortality from cardiovascular diseases and all causes: the Zutphen Elderly Study. Arch Intern Med. 158(14):1998;1499-1505.
13. Blair S.N., Kohl H.W. III, Barlow C.E., Paffembarger R.S., Gibbons L.W., Macer C.A. Changes in physical fitness and all-cause mortality. JAMA. 273:1995;1093-1098.
14. Bogardus C., Lillioja S., Mott D.M., Hollenbeck C., Reaven G. Relationship between degree of obesity and in vivo insulin action in man. Am J Physiol. 248(3):1985;E286-E291. (Pt. 1).
15. Bonadonna R., Groop L., Kraemer N., Ferranini E., DelPrato S., DeFronzo R. Obesity and insulin resistance in humans: a dose-response study. Metabolism. 39(5):1990;452-458.
16. Bray G.A. Historical framework for the development of ideas about obesity. Bray G.A., Bouchard C., James W.P.T. Handbook of Obesity. vol. 1:1997;Marcel Dekker, New York, NY.
17. Bray G.A., Popkin B.M. Dietary fat intake does affect obesity! Am J Clin Nutr. 68(6):1998;1157-1173.
18. Canovatchel W. Long-term tolerability profile of orlistat, an intestinal lipase inhibitor. Diabetologia. 40:1997;A196.
19. Caro J.F., Sinha M.K., Raju S.M., Ittoop O., Pories W.J., Flickinger E.G., Meelheim D., Dohm G.L. Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin dependent diabetes. J Clin Invest. 79(5):1987;1330-1337.
20. Carpino N., Wisniewski D., Strife A., Marshak D., Kobayashi R., Stillman B., Clarkson B. p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell. 88(2):1997;197-204.
21. Celi F.S., Silver K., Waltson J., Knowler W.C., Bogardus C., Shuldiner A.R. Lack of IRS-1 codon 513 and 972 polymorphism in Pima Indians. J Clin Endocrinol Metab. 80:1995;2827-2829.
22. Trends in ischemic heart disease deaths - United States. JAMA. 277(14):1997;1109.
23. Chakravarti A. Population genetics-making sense out of sequence. Nat Genet. 21(Suppl. 1):1999;56-60. January.
24. Chandalia M., Abate N., Garg A., Stray-Gundersen J., Grundy S.M. Relationship between generalized and upper body obesity to insulin resistance in Asian Indian men. J Clin Endocrinol Metab July. 84(7):1999;2329-2335.
25. Charles M.A., Fontbonne A., Thibult N., Warnet J.M., Rosselin G.E., Eschwege E. Risk factors for NIDDM in white population. Paris prospective study. Diabetes. 40(7):1991;796-799.
26. Ciaraldi T., Henry R.R. Thiazolidinediones and their effects on glucose transporters. Eur J Endocrinol. 137(6):1997;610-612.
27. Collins V., Dowse G., Finch C., Zimmet P. An inconsistent relationship between insulin and blood pressure in three pacific island populations. J Clin Epidemiol. 43(12):1990;1369-1378.
28. Changing America: Indicators of Social and Economic Well-Being by Race and Hispanic Origin. 1998;CEA Publication, Washington DC. September.
29. Danielsen A.G., Liu F., Hosomi Y., Shii K., Roth R.A. Activation of protein kinase C alpha inhibits signaling by members of the insulin receptor family. J Biol Chem. 270(37):1995;21600-21605.
30. Despres J.P., Lamarche B., Mauriege P., Cantin B., Dagenais G.R., Moorjani S., Lupien P.J. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 334(15):1996;952-957.
31. Doria A., Caldwell J.S., Reynett C., Rish S.S., Weremowicz S., Morton C.C., Warram J.H., Kahn C.R., Krolewski A.S. Trinucleotide repeats at the rad locus. Allele distribution in NIDDM and mapping to a 3-cM region on chromosome 16q. Diabetes. 44:1995;243-247.
32. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 279(20):1998;1615-1622.
33. Dresner A., Laurent D., Marcucci M., Griffin M.E., Dufour S., Cline G.W., Slezak L.A., Andersen D.K., Hundal R.S., Rothman D.L., Petersen K.F., Shulman G.I. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest. 103(2):1999;253-259.
34. Eckel R.H., Krauss R.M. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. Circulation. 97:1998;2099-2100.
35. Edwards K.L., Austin M.A., Newman B., Mayer E., Krauss R.M., Selby J.V. Multivariate analysis of the insulin resistance syndrome in women. Arterioscler Thromb. 14:1994;1940-1945. MJ65.
36. Ferranini E., Haffner S.M., Stern M., Mitchell B.D., Natali A., Hazuda H.P. High blood pressure and insulin resistance: influence of ethnic background. Eur J Clin Invest. 21:1991;280-287.
37. Feskens E.J., Loeber J.G., Kromhout D. Diet and physical activity as determinants of hyperinsulinemia: the Zutphen Elderly Study. Am J Epidemiol. 140(4):1994;350-360.
38. Fontbonne A.M., Eschwege E.M. Insulin and cardiovascular disease. Paris prospective study. Diabetes Care. 14(6):1991;461-469.
39. Fujimoto W.Y. The growing prevalence of non-insulin-dependent diabetes in migrant Asian populations and its implications for Asia. Diabetes Res Clin Pract. 15:1992;167-184. MJ57.
40. Fujimoto W.Y., Bergstrom R.W., Boyko E.J., Kinyoun J.L., Leonetti D.L., Newell-Morris L., Robinson L., Shuman W.P., Stolov W.C., Tsunehara C.H., Wahl P.W. Diabetes and diabetes risk factors in second- and third-generation Japanese Americans in Seattle, Washington. Diabetes Res Clin Pract. 24:1994;S43-S52. MJ55.
41. Fukagawa N.K., Anderson J.W., Hageman G., Young V.R., Minaker K.L. High-carbohydrate, high-fiber diets increase peripheral insulin sensitivity in healthy young and old adults. Am J Clin Nutr. 52(3):1990;524-528.
42. Gaster B., Hirsch I.B. The effects of improved glycemic control in complications of type 2 diabetes. Arch Intern Med. 158:1998;134-140.
43. Gelding S.V., Coldham N., Niththyananthan R., Anyaoku V., Johnston D.G. Insulin resistance with respect to lipolysis in non-diabetic relatives of European patients with type 2 diabetes. Diabetes Med. 12(1):1995;66-73.
44. Golay A., Swislocki A.L., Chen Y.D., Jaspan J.B., Reaven G.M. Effect of obesity on ambient plasma glucose, free fatty acid, insulin, growth hormone, and glucagon concentrations. J Clin Endocrinol Metab. 63(2):1986;481-484.
45. Goldstein B.J. Regulation of insulin receptor signaling by protein-tyrosine dephosphorylation. Receptor. 3(1):1993;1-15.
46. Goodpaster B.H., Thaete F.L., Simoneau J.A., Kelley D.E. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes. 46:1997;1579-1585.
47. Goodyear L.J., Giorgino F., Sherman L.A., Carey J., Smith R.J., Dohm G.L. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest. 95(5):1995;2195-2204.
48. Gray R.S., Fabsitz R., Cowan L., Lee E.T., Howard B., Savage P. Risk factor clustering in the insulin resistance syndrome. Am J Epidemiol. 148:1998;869-878. MJ66.
49. Grey N., Kipnis D.M. Effect of diet composition on the hyperinsulinemia of obesity. N Engl J Med. 285(15):1971;827-831.
50. Guerciolini R. Mode of action of orlistat. Int J Obes Relat Metab Disord. 21(Suppl. 3):1997;S12-S23.
51. Gulli G., Ferranini E., Stern M., Haffner S., DeFronzo R.A. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes. 41(12):1992;1575-1586.
52. Haffner S.M., D'Agostino R. Jr., Mykkanen L., Tracy R., Howard B., Rewers M., Selby J., Savage P.J., Saad M.F. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 22(4):1999;562-568.
53. Haffner S., D'Agostino R., Saad M.F., Rewers M., Mykkanen L., Selby J., Howard G., Savage P., Hamman R., Wagenknecht L., Bergman R. Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites: the Insulin Resistance Atherosclerosis Study. Diabetes. 45:1996;742-748.
54. Haffner S.M., Miettinen H., Stern M.P. Nondiabetic Mexican-Americans do not have reduced insulin responses relative to nondiabetic non-Hispanic whites. Diabetes Care. 19(1):1996;67-69.
55. Haffner S.M., Stern M.P., Mitchell B.D., Hazuda H.P., Patterson J.K. Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body fat distribution. Diabetes. 39(3):1990;283-288.
56. Hager J., Zouali H., Velho G., Froguel P. Insulin receptor substrate (IRS-1) gene polymorphism in French NIDDM families. Lancet. 342:1993;1430.
57. Hall J.E., Louis K. Renal and cardiovascular mechanisms of hypertension in obesity. Hypertension. 23(3):1994;381-394.
58. Handberg A., Vaag A., Vinten J., Beck-Nielsen H. Decreased tyrosine kinase activity in partially purified insulin receptors from muscle of young, non-obese first degree relatives of patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 36(7):1993;668-674.
59. Hansen T., Andersen C.B., Echwald S.M., Urhammer S., Clausen J.O., Vestergaard H., Owens D., Hansen L., Pedersen O. Identification of a common amino acid polymorphism in the p85alpha regulatory subunit of phosphatidylinositol 3-kinase: effects on glucose disappearance constant, glucose effectiveness, and the insulin sensitivity index. Diabetes. 46:1997;494-501.
60. Hauptman J., Guerciolini R., Nicholas G. Orlistat: a novel treatment for obesity. Nutrition Genetics and Obesity. 1998;Louisiana State Press, Baton Rouge, LA.
61. Hayashi T., Hirshman M.F., Kurth E.J., Winder W.W., Goodyear L.J. Evidence for 5′ AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes. 47(8):1998;1369-1373.
62. Hirshman M.F., Fagnant P.M., Horton E.D., King P.A., Horton E.S. Pioglitazone treatment for 7 days failed to correct the defect in glucose transport and glucose transporter translocation in obese Zucker rat (fa/fa) skeletal muscle plasma membranes. Biochem Biophys Res Commun. 208(2):1995;835-845.
63. Hitman G.A., Hawrami K., McKarthy M.I., Viswanathan M., Snehalatha C., Ramachandran A., Tuomilehto E., Tuomilehto-Wolf E. Insulin receptor substrate-1 gene mutations in NIDDM: implications for the study of polygenic disease. Diabetologia. 38:1995;481-486.
64. Hofmann C., Lorenz K., Colca J.R. Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone. Endocrinology. 129(4):1991;1915-1925.
65. Holgado-Madruga M., Emlet D.R., Moscatello D.K., Godwin A.K., Wong A.J. A Grb2-associated docking protein in EGF- and insulin-receptor signaling. Nature. 379(6565):1996;560-564.
66. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 95(5):1995;2409-2415.
67. Howard B.V., Davis M.P., Pettit D.J., Knowler W.C., Bennett P.H. Plasma and lipoprotein cholesterol and triglyceride concentrations in the Pima Indians: distributions differing from those of Caucasians. Circulation. 68(4):1983;714-724.
68. Howard B.V., Knowler W.C., Vasquez B., Kennedy A.L., Pettitt D.J., Bennett P.H. Plasma and lipoprotein cholesterol and triglyceride in the Pima Indian population. Comparison of diabetics and nondiabetics. Arteriosclerosis. 4(5):1984;462-471.
69. Howard B.V., Lee E.T., Yeh J.L., Go O., Fabsitz R.R., Devereux R.B., Welty T.K. Hypertension in adult American Indians. The Strong Heart Study. Hypertension. 28(2):1996;256-264.
70. Howard G., O'Leary D.H., Zaccaro D., Haffner S., Rewers M., Hamman R., Selby J.V., Saad M.F., Savage P., Bergman R. Insulin sensitivity and atherosclerosis. The Insulin Resistance and Atherosclerosis Study (IRAS) Investigators. Circulation. 93(10):1996;1809-1817.
71. Hsueh W., Law R.E. Insulin signaling in the arterial wall. Am J Cardiol. 84:1999;21J-24J.
72. Hurrell D.G., Pedersen O., Kahn C.R. Alterations in the hepatic insulin receptor kinase in genetic and acquired obesity in rats. Endocrinology. 125(5):1989;2454-2462.
73. Imai Y., Frusco A., Suzuki Y., Lesniak M.A., D'Alfonso R., Sesti G., Bertoli A., Lauro R., Accili D., Taylor S.I. Variant sequences of insulin receptor substrate-1 in patients with noninsulin dependent diabetes mellitus. J Clin Endocrinol Metab. 79:1994;1655-1658.
74. Inzucchi S.E., Maggs D.G., Spollett G.R., Page S.L., Rife F.S., Walton V., Shulman G.I. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 338(13):1998;867-872.
75. Ishikawa M., Pruneda M.L., Adams-Huet B., Raskin P. Obesity-independent hyperinsulinemia in nondiabetic first-degree relatives of individuals with type 2 diabetes. Diabetes. 47(5):1998;788-792.
76. The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 157:1997;2413-2446.
77. Juhan-Vague I., Alessi M.C., Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med. 28(4):1996;371-380.
78. Kalidas K., Wasson J., Glaser B., Meyer J.M., Duprat L.J., White M.F., Permutt M.A. Mapping of the human insulin receptor substrate-2 gene, identification of a linked polymorphic marker and linkage analysis in families with type II diabetes: no evidence for a major susceptibility role. Diabetologia. 41:1998;1389-1391.
79. Kanety H., Feinstein R., Papa M.Z., Hemi R., Karasik A. Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem. 270(40):1995;23780-23784.
80. Kasuga M., Fujita-Yamaguchi Y., Blithe D.L., Kahn C.R. Tyrosine-specific protein kinase activity is associated with the purified insulin receptor. Proc Natl Acad Sci USA. 80(8):1983;2137-2141.
81. Kenny S.L. Diabetes Am. 2:1995;47-67.
82. Kishi K., Muromoto N., Nakaya Y., Miyata I., Hagi A., Hayashi H., Ebina Y. Bradykinin directly triggers GLUT4 translocation via an insulin-independent pathway. Diabetes. 47(4):1998;550-558.
83. Kitazawa Y., Murakami K., Goto Y., Hamazaki S. Prevalence of diabetes mellitus detected by 75 g GGT in Tokyo. Tohoku J. Exp. Med. Dec. 141:1983;229-234. (Suppl.).
84. Krook A., O'Rahilly S. Mutant insulin receptors in syndromes of insulin resistance. Baillier's Clin Endocrinol Metab. 10:1996;97-122.
85. Kumakura S., Maddux B.A., Sung C.K. Overexpression of membrane glycoprotein PC-1 can influence insulin action at a post-receptor site. J Cell Biochem. 3:1998;366-377.
86. Laakso M., Malkki M., Kekalainen P., Kuusisto J., Deeb S.S. Insulin receptor substrate-1 variants in non-insulin-dependent diabetes. J Clin Invest. 94:1994;1141-1146.
87. Lander E.S., Schork N.J. Genetic dissection of complex traits. Science. 265:1994;2037-2048.
88. Lapidus L., Bengtsson C., Larsson B., Pennert K., Rybo E., Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow-up of participants in the population study of women in Gothenburg, Sweden. BMJ. 289:1984;1257-1261.
89. Lavan B.E., Fantin V.R., Chang E.T., Lane W.S., Keller S.R., Lienhard G.E. A novel 160-kDa phosphotyrosine protein in insulin-treated embryonic kidney cells is a new member of the insulin receptor substrate family. J Biol Chem. 22/272(34):1997;21403-21407.
90. Lavan B.E., Lane W.S., Lienhard G.E. The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family. J Biol Chem. 272(17):1997;11439-11443.
91. Law R.E., Meehan W.P., Xi X.P., Graf K., Wuthrich D.A., Coats W., Faxon D., Hsueh W.A. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 98(8):1996;1897-1905.
92. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 270(22):1995;12953-12956.
93. Lillioja S., Mott D.M., Spraul M., Ferraro R., Foley J.E., Ravussin E., Knowler W.C., Bennett P.H., Bogardus C. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med. 329(27):1993;1988-1992.
94. Lindsted K., Tonstad S., Kuzma J.W. Body mass index and patterns of mortality among Seventh Day Adventist men. Int J Obes. 15:1991;397-406.
95. Lovejoy J., DiGirolamo M. Habitual dietary intake and insulin sensitivity in lean and obese adults. Am J Clin Nutr. 55(6):1992;1174-1179.
96. Lund S., Holman G.D., Schmitz O., Pedersen O. Contraction stimulates translocation of glucose transporter GLUT4 in skeletal muscle through a mechanism distinct from that of insulin. Proc Natl Acad Sci USA. 92(13):1995;5817. June 20.
97. Maddux B.A., Sbraccia P., Kamakura S., Sasson S., Youngren J., Fisher A., Spencer S., Grupe A., Henzel W., Stewart T.A. Membrane glycoprotein PC-1 in the insulin resistance of non-insulin dependent diabetes mellitus. Nature. 373:1995;448-451.
98. Manninen V., Tenkanen L., Koskinen P., Huttunen J.K., Manttari M., Heinonen O.P., Frick M.H. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 85(1):1992;37-45.
99. Manson J.E., Willett W.C., Stampfer M.J., Golditz G.A., Huter D.J., Hankinson S.E., Colditz G.A., Hunter D.J., Hankinson S.E., Hennekens C.H., Speizer F.E. Body weight and mortality among women. N Engl J Med. 333:1995;677-685.
100. Mayer E.J., Newman B., Quesenberry C.P. Jr., Selby J.V. Usual dietary fat intake and insulin concentrations in healthy women twins. Diabetes Care. 16(11):1993;1459-1469.
101. Mayer-Davis E.J., D'Agostino R. Jr., Karter A.J., Haffner S.M., Rewers M.J., Saad M.F., Bergman R.N. Intensity and amount of physical activity in relation to insulin sensitivity: the Insulin Resistance and Atherosclerosis Study. JAMA. 279(9):1998;669-674.
102. Mayer-Davis E.J., Monaco J.H., Hoen H.M., Carmichael S., Vitolins M.Z., Rewers M.J., Haffner S.M., Ayad M.F., Bergman R.N., Karter A.J. Dietary fat and insulin sensitivity in a triethnic population: the role of obesity. The Insulin Resistance and Atherosclerosis Study (IRAS). Am J Clin Nutr. 65(1):1997;79-87.
103. McKeigue P.M., Shah B., Marmot M.G. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet. 337:1991;382-386. MJ44.
104. Meigs J.B., D'Agostino R., Wilson P.W.F., Cupples L.A., Nathan D.M., Singer D.E. Risk variable clustering in the insulin resistance syndrome (The Framingham Offspring Study). Diabetes. 46:1997;1594-1600.
105. Minamikawa J., Tanaka S., Yamauchi M., Inoue D., Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 83(5):1998;1818-1820.
106. Mokdad A.H., Serdula M.K., Dietz W.H., Bowman B.A., Marks J.S., Koplan J.P. The spread of the obesity epidemic in the United States, 1991-1998. JAMA. 282(16):1999;1519-1522.
107. Moyers J.S., Bilan P.J., Reynet C., Kahn C.R. Overexpression of Rad inhibits glucose uptake in cultured muscle and fat cells. J Biol Chem. 271:1996;23111-23116.
108. Must A., Spadano J., Coakley E.H., Field A.E., Colditz G., Dietz W.H. The disease burden associated with overweight and obesity. JAMA. 282(16):1999;1523-1529. October 27.
109. Nagulesparan M., Savage P., Knowler W., Johnson G.C., Bennett P. Increased in vivo insulin resistance in nondiabetic Pima Indians. Diabetes. 31:1982;952-956. MJ6.
110. Advance Report of final mortality statistics, 1990. Mon Vital Stat Rep. 41(7):1993;. (Suppl.).
111. Neel J.V. Diabetes mellitus: a thrifty genotype rendered detrimental by progress? Am J Hum Genet. 14:1962;353-362.
112. Nickenig G., Roling J., Strehlow K., Schnabel P., Bohm M. Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation. 98(22):1998;2453-2460.
113. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med. 115:1991;956.
114. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults - evidence report. Obes Res. 6(Suppl. 2):1998;51S-209S.
115. Olefsky J.M. Decreased insulin binding to adipocytes and circulating monocytes from obese subjects. J Clin Invest. 57(5):1976;1165-1172.
116. Pelicci G., Lanfrancone L., Grignani F., McGlade J., Cavallo F., Forni G., Nicoletti I., Grignani F., Pawson T. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell. 70(1):1992;93-104.
117. Peraldi P., Spiegelman B. TNF-alpha and insulin resistance: summary and future prospects. Mol Cell Biochem. 182(1-2):1998;169-175.
118. Pyorala M., Miettinen H., Laakso M., Pyorala K. Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Circulation. 98(5):1998;398-404.
119. Pyorala K., Savolainen E., Kaukola S., Haapakoski J. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9 1/2-year follow-up of the Helsinki Policemen Study population. Acta Med Scand, Suppl. 701:1985;38-52.
120. Ravussin E., Valencia M.E., Esparza J., Bennett P.H., Schulz L.O. Effects of a traditional lifestyle on obesity in Pima Indians. Diabetes Care. 17(9):1994;1067-1074.
121. Reaven G.M. The role of insulin resistance in human disease. Diabetes. 37:1998;1595-1607.
122. Reaven G.M., Chen Y.D., Jeppesen J., Maheux P., Krauss R.M. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest. 92(1):1993;141-146.
123. Reaven G.M., Lithell H., Landsberg L. Hypertension and associated metabolic abnormalities - the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 334(6):1996;374-381.
124. Rexrode K.M., Carey V.J., Hennekens C.H., Walters E.E., Colditz G.A., Stampfer M.J., Walters E.E., Colditz G.A., Stampfer M.J., Willett W.C., Manson J.E. Abdominal adiposity and coronary heart disease in women. JAMA. 280:1998;1843-1848.
125. Reynet C., Kahn C.R. Rad: a member of the ras family overexpressed in muscle of type II diabetic humans. Science. 262:1993;1441-1444.
126. Rosen O.M. Structure and function of insulin receptors. Diabetes. 38(12):1989;1508-1511.
127. Rosenthal M., Haskell W.L., Solomon R., Widstrom A., Reaven G.M. Demonstration of a relationship between level of physical training and insulin-stimulated glucose utilization in normal humans. Diabetes. 32(5):1983;408-411.
128. Rothenberg P.L., Lane W.S., Karasik A., Backer J., White M., Kahn C.R. Purification and partial sequence analysis of pp185, the major cellular substrate of the insulin receptor tyrosine kinase. J Biol Chem. 266(13):1991;8302-8311.
129. Rubins H.B., Robins J.S., Collins D., Fye C.L., Anderson J.W., Elam M.B., Faas F.H., Linares E., Schaefer E.J., Schectman G., Wilt T.J., Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 341:1999;410-418.
130. Saad M.F., Lillioja S., Nyomba B., Castillo C., Ferraro R., Gregorio M., Ravussin E., Knowler W., Bennet P., Howard B., Bogardus C. Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med. 324:1991;733-739.
131. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Aronld J.M., Wun C.C., Davis B.R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med. 335(14):1996;1001-1009.
132. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. The Scandinavian Simvastatin Survival Study (4S). Lancet. 344(8934):1994;1383-1389.
133. Scherrer U., Randin D., Vollenweider P., Vollenweider L., Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest. 94(6):1994;2511-2515.
134. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 333(20):1995;1301-1307.
135. Shiomi M., Ito T., Tsukada T., Tsujita Y., Horikoshi H. Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits. Atherosclerosis. 142(2):1999;345-353.
136. Sicree R.A., Zimmet P.Z., King H.O., Coventry J.S. Plasma insulin response among Nauruans. Prediction of deterioration in glucose tolerance over 6 yr. Diabetes. 36(2):1987;179-186.
137. Smith S.C. Jr., Blair S.N., Criqui M.H., Fletcher G.F., Fuster V., Gersh B.J., Gotto A.M., Gould K.L., Greenland P., Grundy S.M. Preventing heart attack and death in patients with coronary disease. Circulation. 92(1):1995;2-4.
138. Steinberg H.O., Tarshoby M., Monestel R., Hook G., Cronin J., Johnson A., Baazeed B., Baron A.D. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest. 100(5):1997;1230-1239.
139. Stevens J., Cai J., Pamuk E.R., Williamson D.F., Thun M.J., Wood J.L. The effect of age on the association between body-mass index and mortality. N Engl J Med. 338:1998;1.
140. Sun X.J., Miralpeix M., Myers M.G. Jr., Glasheen E.M., Backer J.M., Kahn C.R., White M.F. Expression and function of IRS-1 in insulin signal transmission. J Biol Chem. 267(31):1992;22662-22672.
141. Sun X.J., Wang L.M., Zhang Y., Yenush L., Myers M.G. Jr., Glasheen E., Lane W.S., Pierce J.H., White M.F. Role of IRS-2 in insulin and cytokine signaling. Nature. 377(6545):1995;173-177.
142. Swinburn B.A., Boyce V.L., Bergman R.N., Howard B.V., Bogardus C. Deterioration in carbohydrate metabolism and lipoprotein changes induced by modern, high fat diet in Pima Indians and Caucasians. J Clin Endocrinol Metab. 73(1):1991;156-165.
143. Szalkowski D., White-Carrington S., Berger J., Zhang B. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology. 136(4):1995;1474-1481.
144. Tanaka T., Itoh H., Doi K., Fukunaga Y., Hosoda K., Shintani M., Yamashita J., Chun T.H., Inoue M. Down regulation of peroxisome proliferator-activated receptor gamma expression by inflammatory cytokines and its reversal by thiazolidinediones. Diabetologia. 42(6):1999;702-710.
145. Tenkanen L., Manttari M., Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation. 92(7):1995;1779-1785.
146. The Expert Panel, 1993. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. NIH Publication No. 93-3095. US Government Printing Office, Washington, DC.
147. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 339(19):1998;1349-1357.
148. Thorell A., Hirshman M.F., Nygren J., Jorfeldt L., Wojtaszewski J.F., Dufresne S.D., Horton E.S., Ljungqvist O., Goodyear L.J. Exercise and insulin cause GLUT-4 translocation in human skeletal muscle. Am J Physiol. 277(4):1999;E733-E741. (Pt. 1).
149. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., Evans R.M. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 93(2):1998;241-252.
150. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 352(9131):1998;854-865.
151. Ullrich A., Bell J.R., Chen E.Y., Herrera R., Petruzzelli L.M., Dull T.J., Gray A., Coussen L., Liao Y.C., Tsubokawa M. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature. 313(6005):1985;756-761.
152. Ura S., Araki E., Kishikaua H., Shirotani T., Todaka M., Isami S., Shimoda A., Yoshimura R., Matsuda K., Motoyoshi S., Miyamura N., Kahn C.R., Shichiri M. Molecular scanning of the IRS-1 gene in Japanese patients with non-insulin-dependent diabetes mellitus: identification of five novel mutations in IRS-1 gene. Diabetologia. 39:1996;600-608.
153. Utriainen T., Holmang A., Bjorntorp P., Makimattila S., Sovijarvi A., Lindholm H., Yki-Jarvinen H. Physical fitness, muscle morphology, and insulin-stimulated limb blood flow in normal subjects. Am J Physiol. 270(5):1996;E905-E911. (Pt. 1).
154. Vaag A., Henriksen J.E., Beck-Nielsen H. Decreased insulin activation of glycogen synthase in skeletal muscles in young nonobese Caucasian first-degree relatives of patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 89(3):1992;782-788.
155. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr. 4(1):1956;20-34.
156. Valdez R., Gonzales-Villalpando, Mitchell B.D., Haffner S., Stern M. Differential impact of obesity in related populations. Obes Res. 3(Suppl. 2):1995;223S-232S.
157. Willett W.C., Manson J.E., Stampfer M.J., Colditz G.A., Rosner B., Speizer F.E., Colditz G.A., Rosner B., Speizer F.E., Hennekens C.H. Weight, weight change and coronary heart disease in women: risk within the normal weight range. JAMA. 273:1995;461-465.
158. Wojtaszewski J.F., Higaki Y., Hirshman M.F., Michael M.D., Dufresne S.D., Kahn C.R., Goodyear L.J. Exercise modulates postreceptor insulin signaling and glucose transport in muscle-specific insulin receptor knockout mice. J Clin Invest. 104(9):1999;1257-1264.
159. Yki-Jarvinen H., Koivisto V.A. Effects of body composition on insulin sensitivity. Diabetes. 32(10):1983;965-969.
160. Young M.E., Radda G.K., Leighton B. Nitric oxide stimulates glucose transport and metabolism in rat skeletal muscle in vitro. Biochem J. 322:1997;223-238. (Pt. 1).
161. Yoshimura R., Araki E., Ura S., Todaka M., Tsuruzoe K., Furukawa N., Motoshima H., Yoshizato K., Kaneko K., Matsuda K., Kishikaua H., Shichiri M. Impact of natural IRS-1 mutations of insulin signals: mutations of IRS-1 in the PTB domain and near SH2 protein binding sites result in impaired function at different steps of IRS-1 signaling. Diabetes. 46:1997;929-936.
162. Yusuf H.R., Giles W.H., Croft J.B., Anda R.F., Casper M.L. Impact of multiple risk factor profiles on determining cardiovascular disease risk. Prev Med. 27:1998;1-9. MJ68.
163. Zavaroni I., Dall'Aglio E., Alpi O., Bruschi F., Bonora E., Pezzarossa A., Butturini U. Evidence for an independent relationship between plasma insulin and concentration of high density lipoprotein cholesterol and triglyceride. Atherosclerosis. 55(3):1985;259-266.